Medcura, Inc. Receives Grant to Develop New Internal Use Hemostats

Medcura Inc. announces two new grants that support the development of internal use hemostats. Medcura has been awarded a $1.4M grant from the Department of Defense (DoD) through the US Army Medical Research and Material Command (USAMRMC) to develop advanced solutions for prolonged field care. The grant supports the development of an expanding foam hemostat for the treatment of internal non-compressible hemorrhage. Internal non-compressible hemorrhage typically results from being struck by shrapnel or a significant concussive force. As an expansion of Medcura’s hemostatic platform (see existing FDA clearances at https://www.medcurainc.com/news.html), the Company has been optimizing flowable formulations for internal and surgical use. Consequently, certain product candidates have been identified that can be administered in far-forward locations to quickly stabilize internal injuries, allowing time for evacuation of the wounded to a field surgical OR.Learn more about Medcura’s product pipeline at https://medcurainc.com/solutions“We are honored to be working with our military to develop such an important hemostatic application. This project is a natural extension of our previously published work using flowable formulations, from our biopolymer-based platform, to treat aggressive internal bleeding.” said Dr. Matthew Dowling, CSO of Medcura. “It is gratifying to have the DoD recognize our technology platform and support the synergy of this project with the expansion of our product line from the broad treatment of external wounds to those arising from combat.”“Internal non-compressible hemorrhage remains the single largest cause of in-combat hemorrhage-related death,” said Dr. David King, MD, LTC and former Chief, Division of Trauma Surgery, 86th Combat Support Hospital, Baghdad, Iraq. “The evaluation of new approaches, like the one Medcura is using, will be important to improve outcomes for our wounded service men and women, both on and off the battlefield.”Medcura has also been awarded an expansion of its SBIR Phase II grant, to support additional seminal research into the development of new flowable, internal-use hemostatic formulations. This award by the National Science Foundation, is based on the Company’s previous success as a Phase I and II recipient.